全文获取类型
收费全文 | 3471篇 |
免费 | 311篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 170篇 |
妇产科学 | 64篇 |
基础医学 | 383篇 |
口腔科学 | 134篇 |
临床医学 | 324篇 |
内科学 | 841篇 |
皮肤病学 | 26篇 |
神经病学 | 384篇 |
特种医学 | 49篇 |
外科学 | 455篇 |
综合类 | 22篇 |
一般理论 | 11篇 |
预防医学 | 411篇 |
眼科学 | 96篇 |
药学 | 173篇 |
中国医学 | 10篇 |
肿瘤学 | 235篇 |
出版年
2021年 | 46篇 |
2020年 | 39篇 |
2019年 | 36篇 |
2018年 | 61篇 |
2017年 | 55篇 |
2016年 | 56篇 |
2015年 | 59篇 |
2014年 | 96篇 |
2013年 | 144篇 |
2012年 | 205篇 |
2011年 | 224篇 |
2010年 | 132篇 |
2009年 | 101篇 |
2008年 | 215篇 |
2007年 | 186篇 |
2006年 | 220篇 |
2005年 | 228篇 |
2004年 | 221篇 |
2003年 | 200篇 |
2002年 | 214篇 |
2001年 | 33篇 |
2000年 | 18篇 |
1999年 | 33篇 |
1998年 | 63篇 |
1997年 | 45篇 |
1996年 | 48篇 |
1995年 | 39篇 |
1994年 | 36篇 |
1993年 | 34篇 |
1992年 | 25篇 |
1991年 | 16篇 |
1989年 | 23篇 |
1988年 | 21篇 |
1986年 | 18篇 |
1985年 | 23篇 |
1984年 | 36篇 |
1983年 | 20篇 |
1982年 | 36篇 |
1981年 | 24篇 |
1980年 | 26篇 |
1979年 | 21篇 |
1978年 | 26篇 |
1977年 | 23篇 |
1974年 | 18篇 |
1973年 | 20篇 |
1970年 | 15篇 |
1942年 | 15篇 |
1940年 | 17篇 |
1929年 | 14篇 |
1928年 | 16篇 |
排序方式: 共有3809条查询结果,搜索用时 15 毫秒
51.
Iris Schrijver Nazneen Aziz Daniel H. Farkas Manohar Furtado Andrea Ferreira Gonzalez Timothy C. Greiner Wayne W. Grody Tina Hambuch Lisa Kalman Jeffrey A. Kant Roger D. Klein Debra G.B. Leonard Ira M. Lubin Rong Mao Narasimhan Nagan Victoria M. Pratt Mark E. Sobel Karl V. Voelkerding Jane S. Gibson 《The Journal of molecular diagnostics : JMD》2012,14(6):525-540
52.
Onda M Beers R Xiang L Nagata S Wang QC Pastan I 《Proceedings of the National Academy of Sciences of the United States of America》2008,105(32):11311-11316
Recombinant immunotoxins are hybrid proteins composed of an Fv that binds to a tumor antigen fused to a bacterial or plant toxin. Immunotoxin BL22 targets CD22 positive malignancies and is composed of an anti-CD22 Fv fused to a 38-kDa fragment of Pseudomonas exotoxin A (PE38). BL22 has produced many complete remissions in drug-resistant Hairy cell leukemia, where many treatment cycles can be given, because neutralizing antibodies do not form. In marked contrast, only minor responses have been observed in trials with immunotoxins targeting solid tumors, because only a single treatment cycle can be given before antibodies develop. To allow more treatment cycles and increase efficacy, we have produced a less immunogenic immunotoxin by identifying and eliminating most of the B cell epitopes on PE38. This was accomplished by mutation of specific large hydrophilic amino acids (Arg, Gln, Glu, Lys) to Ala, Ser, or Gly. The new immunotoxin (HA22-8X) is significantly less immunogenic in three strains of mice, yet retains full cytotoxic and anti-tumor activities. Elimination of B-cell epitopes is a promising approach to the production of less immunogenic proteins for therapeutic purposes. 相似文献
53.
Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity 总被引:1,自引:0,他引:1
Bingham A Mamyrova G Rother KI Oral E Cochran E Premkumar A Kleiner D James-Newton L Targoff IN Pandey JP Carrick DM Sebring N O'Hanlon TP Ruiz-Hidalgo M Turner M Gordon LB Laborda J Bauer SR Blackshear PJ Imundo L Miller FW Rider LG;Childhood Myositis Heterogeneity Study Group 《Medicine》2008,87(2):70-86
We describe the clinical features of 28 patients with juvenile dermatomyositis (JDM) and 1 patient with adult-onset dermatomyositis (DM), all of whom developed lipodystrophy (LD) that could be categorized into 1 of 3 phenotypes, generalized, partial, or focal, based on the pattern of fat loss distribution. LD onset was often delayed, beginning a median of 4.6 years after diagnosis of DM. Calcinosis, muscle atrophy, joint contractures, and facial rash were DM disease features found to be associated with LD. Panniculitis was associated with focal lipoatrophy while the anti-p155 autoantibody, a newly described myositis-associated autoantibody, was more associated with generalized LD. Specific LD features such as acanthosis nigricans, hirsutism, fat redistribution, and steatosis/nonalcoholic steatohepatitis were frequent in patients with LD, in a gradient of frequency and severity among the 3 sub-phenotypes. Metabolic studies frequently revealed insulin resistance and hypertriglyceridemia in patients with generalized and partial LD. Regional fat loss from the thighs, with relative sparing of fat loss from the medial thighs, was more frequent in generalized than in partial LD and absent from DM patients without LD. Cytokine polymorphisms, the C3 nephritic factor, insulin receptor antibodies, and lamin mutations did not appear to play a pathogenic role in the development of LD in our patients. LD is an under-recognized sequela of JDM, and certain DM patients with a severe, prolonged clinical course and a high frequency of calcinosis appear to be at greater risk for the development of this complication. High-risk JDM patients should be screened for metabolic abnormalities, which are common in generalized and partial LD and result in much of the LD-associated morbidity. Further study is warranted to investigate the pathogenesis of acquired LD in patients with DM. 相似文献
54.
55.
Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality 总被引:5,自引:0,他引:5
Russo MW Sood A Jacobson IM Brown RS 《The American journal of gastroenterology》2003,98(11):2521-2527
OBJECTIVES: Transjugular intrahepatic portosystemic shunt (TIPS) is frequently used to treat patients with refractory ascites, but its role is controversial. We sought to determine from the literature the efficacy, morbidity, and mortality associated with TIPS for refractory ascites. METHODS: We searched MEDLINE and identified studies published in English from January, 1985, to March, 2003, that evaluated the effect of TIPS in patients with refractory ascites. Outcomes that were analyzed included complete resolution of ascites, reduction in ascites, mortality, encephalopathy, stenosis, and renal function. Data were analyzed on an intention to treat basis. RESULTS: Of 25 studies identified, 16 were included in the analysis. The pooled estimate for complete response at 6 months was 45% and for any response (complete and partial) was 63%. Pooled 6-month mortality after TIPS was 36%. Risk factors for mortality included renal insufficiency (serum creatinine >1.5 mg/dl), hyperbilirubinemia (total bilirubin >3 mg/dl), advanced age (>60 yr), and poor response to TIPS. The pooled rate of new or worsening encephalopathy after TIPS was 32%. In most cases, encephalopathy was managed medically or by reduction in shunt size; however, refractory cases were associated with 100% mortality in most studies. Studies reporting the effect of TIPS on kidney function showed improvement in creatinine clearance and urinary sodium excretion. CONCLUSIONS: TIPS is effective in eliminating ascites or substantially reducing ascites in cases refractory to medical therapy. Renal insufficiency, refractory encephalopathy, and hyperbilirubinemia were consistently associated with mortality after TIPS. In individuals with risk factors for mortality, alternative strategies should be recommended. 相似文献
56.
Intravenous epinephrine in life-threatening asthma 总被引:3,自引:0,他引:3
STUDY OBJECTIVE: Intravenous epinephrine is a potentially vital therapy for patients with life-threatening asthma but is often avoided because of concerns about its safety. We evaluated the safety of intravenous epinephrine in a series of adults with life-threatening asthma. METHODS: We performed an explicit retrospective chart review on a case series of 27 emergency department patients aged 19 to 58 years (mean 25 years) who were treated with intravenous epinephrine for a life-threatening exacerbation of asthma between 1989 and 1997. Explicit criteria for adverse effects, including cardiac arrhythmia or ischemia, hypotension or hypertension, neurologic injury, and death, were defined before chart review. RESULTS: No patient had an arrhythmia other than sinus tachycardia, and there were no cases of cardiac ischemia, hypotension, neurologic deficit, or death. CONCLUSION: Intravenous epinephrine was safe in this small series of younger adults with acute life-threatening asthma. A prospective trial of its use to better define an efficacy and risk-benefit relationship is justified. 相似文献
57.
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated 总被引:3,自引:0,他引:3
Billheimer JT Dicker IB Wynn R Bradley JD Cromley DA Godonis HE Grimminger LC He B Kieras CJ Pedicord DL Spitz SM Thomas BE Zolotarjova NI Gorko MA Hollis GF Daly RN Stern AM Seiffert D 《Blood》2002,99(10):3540-3546
Glycoprotein (GP) IIb/IIIa antagonists are effective therapeutic agents, but elicit thrombocytopenia with a frequency that approaches 2%. Here, we provide evidence that thrombocytopenia in humans treated with the GP IIb/IIIa antagonist roxifiban is immune mediated. Two patients underwent conversion to a highly positive drug-dependent antibody (DDAB) status temporally associated with thrombocytopenia. Despite the continued presence of DDABs, the fall in platelet count was reversed by discontinuation of drug treatment, pointing to the exquisite drug dependency of the immune response. DDABs appear to bind to neoepitopes in GP IIb/IIIa elicited on antagonist binding. This information was used to develop an enzyme-linked immunosorbent assay (ELISA) for DDAB using solid-phase GP IIb/IIIa. A high level of specificity is indicated by the observation that DDAB binding is dependent on the chemical structure of the GP IIb/IIIa antagonist and that only 2% to 5% of human blood donors and 5% of chimpanzees present with pre-existing DDABs. Furthermore, none of 108 nonthrombocytopenic patients from the phase II roxifiban study showed an increase in antibody titer. Absorption of thrombocytopenia plasma with platelets reduced the DDAB ELISA signal, indicating that the test detects physiologically relevant antibodies. Screening patients for pre-existing or increasing DDAB titer during treatment with GP IIb/IIIa antagonists may reduce the incidence of drug-induced thrombocytopenia. 相似文献
58.
Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients
下载免费PDF全文
![点击此处可从《Journal of general internal medicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Wong MD Cunningham WE Shapiro MF Andersen RM Cleary PD Duan N Liu HH Wilson IB Landon BE Wenger NS;HCSUS Consortium 《Journal of general internal medicine》2004,19(4):366-374
BACKGROUND: Current HIV treatment guidelines recommend delaying antiretroviral therapy for nonadherent patients, which some fear may disproportionately affect certain populations and contribute to disparities in care. OBJECTIVES: To examine the relationship of physician's attitude toward prescribing protease inhibitors (PIs) to nonadherent patients with disparities in PI use and with health outcomes. DESIGN: Prospective cohort study. PATIENTS AND SETTING: A national probability sample of HIV-infected adults in the United States and their health care providers was surveyed between January 1996 and January 1998. We analyzed data on 1717 patients eligible for PI treatment and the 367 providers who cared for them. MEASUREMENTS: Providers' attitude toward prescribing PIs to nonadherent patients, time until patients' first receipt of PIs, mortality, and physical health status. MAIN RESULTS: Eighty-nine percent of providers agreed that patient adherence is important in their decision to prescribe PIs (Selective) while 11% disagreed (Nonselective). Patients who had a Selective provider received PIs later than those with a Nonselective provider (P =.05). Adjusting for patient demographics and health characteristics and provider demographics, HIV knowledge, and experience, Latinos, women, and poor patients received PIs later if their provider had a Selective attitude but as soon as others if their provider had a Nonselective attitude. African-American patients received PIs later than whites, irrespective of their providers' prescribing attitude. Patients with Selective providers had similar odds of mortality than those with Nonselective providers (odds ratio, 1.1; 95% confidence interval, 0.6 to 2.0), but had slightly worse adjusted physical health status at follow-up (49.1 vs 50.4, respectively; P =.04), after controlling for baseline physical health status and other patient and provider covariates. CONCLUSIONS: Most providers consider patient adherence an important factor in their decision to prescribe PIs. This attitude appears to account for the relatively later use of PI treatment among Latinos, women, and the poor. Given the rising HIV infection rates among minorities, women, and the poor, further investigation of this treatment strategy and its impact on HIV resistance and outcomes is warranted. 相似文献
59.
FDG‐based quantitative comparison of glucose metabolism in vitro,exemplified by a head‐to‐head comparison between a triple‐negative breast cancer cell line and a non‐malignant foetal cell line
下载免费PDF全文
![点击此处可从《Clinical physiology and functional imaging》网站下载免费的PDF全文](/ch/ext_images/free.gif)
60.